L-Ornithine for Stress, Fatigue, and Sleep: What Trials Show

What the evidence shows

Small randomized trials in healthy adults suggest possible effects on subjective fatigue, mood, and perceived sleep, but the findings are not consistent across outcomes.
The strongest direct sleep evidence comes from self-report questionnaires; a separate study found a modest change in melatonin timing rather than better sleep itself.
Cortisol results are mixed: one worker study reported lower cortisol-related measures, while a newer social-stress trial found no change in salivary cortisol.
Exercise-related fatigue findings should not be generalized to chronic fatigue, daytime sleepiness, or fatigue caused by illness.
The available evidence is limited by small samples, short follow-up, narrow populations, and possible sponsor involvement.
No cited trial establishes L-ornithine as a treatment for insomnia, anxiety, depression, chronic fatigue, or another diagnosed condition.

What the human evidence supports so far

Across the available trials summarized here, L-ornithine has shown possible effects on selected subjective measures of fatigue, mood, and sleep in healthy adults. The findings are not uniform, and they do not establish L-ornithine as a treatment for insomnia, chronic fatigue, anxiety, depression, or any other diagnosed condition.

The strongest common feature of these studies is their use of placebo-controlled designs. Several were randomized and double-blinded, which reduces—but does not eliminate—the risk that expectations or other differences explain the results. The main weaknesses are small samples, short follow-up, reliance on questionnaires or laboratory stress markers, and limited population diversity.

The studies also examined different kinds of fatigue. One tested fatigue after prolonged cycling, another examined fatigue after a laboratory social-stress task, and another recruited workers who already reported slight stress and fatigue. These are not interchangeable outcomes. A reduction in exercise-related fatigue does not automatically translate into better everyday energy, and an improvement on a mood questionnaire does not demonstrate treatment of a clinical disorder.

Overall, the research supports a cautious description: L-ornithine is a plausible subject for further study, with preliminary signals in healthy volunteers. It does not yet support broad claims about reliable stress relief, improved sleep, or treatment of persistent fatigue.

The eight-week worker study examined stress, mood, and perceived sleep

A randomized, double-blind, placebo-controlled trial enrolled 52 apparently healthy Japanese adults aged 30 to 60 who had full-time jobs and reported slight stress and fatigue. Participants were assigned to L-ornithine or placebo for eight weeks. The researchers assessed serum cortisol and DHEA-S, mood using the Profile of Mood States, insomnia symptoms using the Athens Insomnia Scale, and perceived sleep using the Ogri-Shirakawa-Azumi sleep inventory.

The L-ornithine group showed lower serum cortisol and a lower cortisol-to-DHEA-S ratio than the placebo group. The study also reported less anger-hostility and improvements in some perceived sleep measures. However, not every sleep or mood measure differed between groups. Several improvements occurred in both groups, which is compatible with nonspecific effects such as participation, repeated measurement, or expectation.

This was a useful design for an initial human study because it included randomization, blinding, a placebo comparison, repeated measurements, and an eight-week intervention. Its limitations are substantial. The participants were healthy workers rather than people with diagnosed insomnia or a stress-related disorder, sleep was assessed through questionnaires rather than polysomnography or a comparable objective method, and the sample was small. The authors also noted that the study was not large enough for firm conclusions.

The trial therefore provides preliminary evidence for changes in subjective sleep and selected stress-related measures in a narrow population. It does not show that L-ornithine normalizes sleep disorders or produces the same effects in people with chronic fatigue, psychiatric illness, medical disease, or different demographic backgrounds.

Exercise studies suggest a possible effect on physical fatigue

A double-blind, placebo-controlled, two-period crossover study examined 17 healthy volunteers during prolonged cycling exercise. The intervention involved an experimental L-ornithine regimen over eight days, followed by workload testing on two occasions. The investigators measured subjective fatigue, blood markers related to ammonia and energy metabolism, and aspects of cycling performance.

Compared with placebo, L-ornithine was associated with a lower subjective feeling of fatigue after recovery. The paper also reported performance findings in female participants, including a smaller decline in a short maximal-pedaling measure. Changes in blood triacylglycerol, ketone bodies, free fatty acids, and ammonia were interpreted as consistent with altered fuel use and urea-cycle activity.

The study has strengths for testing exercise-induced fatigue: it used a crossover format, placebo control, blinding, and a standardized physical challenge. Crossover trials can reduce the effect of differences between participants because each person serves as their own comparator.

Its relevance is limited to a specific setting. The participants were healthy volunteers, the sample was very small, the fatigue was produced by demanding cycling, and the intervention was brief. A subjective post-exercise rating is not the same as persistent daytime fatigue, post-viral fatigue, sleepiness, or impaired functioning in daily life. The study also cannot establish that the observed metabolic changes caused the reported feeling of reduced fatigue.

The experimental intake amounts reported in this study describe the trial protocol and should not be treated as general dosing instructions.

A 2024 randomized, double-blind, placebo-controlled parallel-group trial enrolled 65 healthy Japanese adults. Participants received L-ornithine or placebo for seven days and then completed the Trier Social Stress Test, a standardized laboratory task involving public speaking and mental arithmetic under social evaluation. Researchers measured salivary cortisol and mood, including the Profile of Mood States fatigue-inertia and anger-hostility scales.

L-ornithine did not significantly change the salivary cortisol response to the stress task. However, compared with placebo, the L-ornithine group had better scores on fatigue-inertia and anger-hostility the following morning. This pattern is important because it separates subjective mood outcomes from a commonly used physiological stress marker: the mood-related findings were positive, while the cortisol result was null.

The study design was stronger than an uncontrolled before-and-after experiment. Randomization, blinding, placebo control, and a standardized stress challenge improve internal validity. The trial was also registered. Nevertheless, the intervention and observation period were short, the sample was still modest, and the participants were healthy volunteers rather than people with a stress-related diagnosis or persistent fatigue.

The paper reports that the study was funded by Kirin Holdings and that the relevant authors were company employees. That does not invalidate the results, but it is a reason to place greater weight on independent replication. The study supports a limited conclusion: L-ornithine may affect some next-day mood and fatigue ratings after acute social stress in healthy adults, while evidence for reducing the biological cortisol response remains inconsistent.

Sleep research includes subjective measures and a circadian marker

The eight-week worker trial is the main direct evidence for sleep quality, but its sleep outcomes were questionnaire-based. A separate randomized, double-blind, placebo-controlled crossover study examined whether L-ornithine influenced the timing of the human central circadian clock. It included 28 healthy adults who completed two seven-day intake periods separated by a washout period. Researchers measured dim-light melatonin onset, a laboratory marker of circadian phase.

The study reported that dim-light melatonin onset was delayed by 15 minutes after the L-ornithine period compared with placebo. This is evidence that the intervention may influence one aspect of circadian timing under controlled conditions. It is not evidence that participants slept longer, fell asleep faster, felt more rested, or experienced better sleep in everyday life.

A shift in melatonin timing can be scientifically interesting without being clinically beneficial. The direction and practical meaning of a small phase change may depend on a person’s existing sleep schedule, light exposure, work pattern, and circadian timing. The study did not establish that L-ornithine corrects jet lag, shift-work problems, insomnia, or another sleep disorder.

Taken together, the sleep literature is preliminary. One small trial reported improvements in selected self-reported sleep measures over eight weeks, while another found a modest change in a circadian biomarker. Objective measures such as actigraphy, polysomnography, sleep efficiency, and sustained daytime functioning remain underrepresented.

What remains uncertain

Several questions prevent strong conclusions about L-ornithine for stress, fatigue, or sleep:

Population: The cited trials primarily studied healthy Japanese adults. They do not establish effects in people with insomnia, anxiety, depression, chronic fatigue syndrome, long COVID, liver disease, kidney disease, or other medical conditions.
Outcome meaning: Many positive findings involved mood or fatigue questionnaires. These outcomes matter, but they are vulnerable to expectancy, repeated testing, and ordinary fluctuation.
Biological mechanism: Cortisol results are inconsistent. One trial reported lower resting cortisol-related measures, whereas the social-stress trial found no reduction in salivary cortisol after the Trier Social Stress Test.
Sleep quality: Evidence for better sleep comes mainly from self-report. The circadian study measured melatonin timing rather than sleep quality or daytime performance.
Durability: Most studies lasted days or weeks. Long-term benefits, loss of effect, and outcomes after stopping remain unclear.
Replication: The evidence base is small, and several studies were connected to supplement manufacturers or ingredient suppliers. Independent, larger trials would make the conclusions more reliable.
Dose-response: Different studies used different experimental regimens, so the available results do not define a generally effective intake pattern. Reported research protocols should not be interpreted as personal dosing advice.

The most defensible interpretation is that L-ornithine has preliminary, context-dependent effects on selected subjective outcomes in healthy volunteers. The evidence is not strong enough to claim dependable improvement in stress, fatigue, or sleep across the general population.

Bottom line for interpreting claims

Human research has established that L-ornithine can be studied safely enough in controlled short-term trials and may influence some measures related to fatigue, mood, cortisol, perceived sleep, and circadian timing. It has not established a consistent clinical benefit for insomnia, chronic fatigue, stress disorders, or other diagnosed conditions.

The best-supported findings are modest and specific: lower subjective fatigue after demanding exercise, improved selected mood and fatigue scores after a social-stress challenge, and better scores on some self-reported sleep measures in healthy workers. These findings come from different populations and experimental contexts, so they should not be combined into a single claim that L-ornithine broadly improves energy or sleep.

Future studies should include larger and more diverse populations, independent investigators, preregistered primary outcomes, objective sleep measurements, longer follow-up, and direct comparisons of different regimens. Until then, L-ornithine is best described as an incompletely studied supplement with preliminary human signals—not as an established treatment or a proven nootropic for stress, fatigue, or sleep.

Sources

About this article

NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.